Clinical Trials

52 enrolled

Breast Neoplasms

NCT07203729 2026-03-16

The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis

184 enrolled

Breast Neoplasms

NCT05810870 2026-03-10

SABINA

14 enrolled

Breast Neoplasms

NCT07441512 2026-03-02

A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation

26 enrolled

Triple Negative Breast Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

24 enrolled

Breast Neoplasms

NCT07333937 2026-01-12

NETHER

35 enrolled

Brest Cancer

NCT03331250 2025-12-23

Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)

13 enrolled 9 charts

Hemangiosarcoma, Hemangioendothelioma, Epithelioid

NCT03202316 2025-12-16

Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer

37 enrolled

Inflammatory Breast Neoplasms

NCT07255612 2025-12-01

Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)

29 enrolled

Breast Neoplasms

NCT02623972 2025-11-25

A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer

22 enrolled 12 charts

Inflammatory Breast Neoplasms

NCT05530057 2025-11-20

ESPERO

180 enrolled

Advanced Breast Cancer

NCT04986579 2025-11-19

Scalp Cooling in MBC

120 enrolled

Breast Neoplasms

NCT01676818 2025-11-06

Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer

32 enrolled 17 charts

Gynecologic

Uterine Cervical Neoplasms

NCT07205185 2025-10-03

A Multicenter, Single-arm, Prospective Phase II Clinical Study of Epalrotokewali Combined With Eribulin, Anlotinib, and Radiotherapy for the Treatment of Patients With Advanced Soft Tissue Sarcoma.

46 enrolled

NCT03899805 2025-08-28

A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas

57 enrolled 14 charts

Leiomyosarcoma, Liposarcoma, Sarcoma, Histiocytoma, Malignant Fibrous

NCT06533722 2025-06-10

Adaptive Therapy for Post-Second-Line Advanced Breast Cancer

10 enrolled

HER2-negative Metastatic Breast Cancer

NCT02061085 2025-06-08

MERIBEL

53 enrolled 11 charts

Breast Neoplasms, Ketosis, Neoplasm Metastasis

NCT03222856 2025-06-05

KELLY

44 enrolled 17 charts

Breast Neoplasms

NCT02299999 2025-01-15

SAFIR02_Breast

1,460 enrolled

Breast Neoplasms

NCT06731153 2024-12-12

JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC

40 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06102824 2024-11-25

ORIENTA

252 enrolled

HER2-negative Breast Cancer

NCT06678230 2024-11-07

Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer

40 enrolled

Breast Neoplasms

NCT01827787 2024-11-06

Eribulin in HER2 Negative Metastatic BrCa

83 enrolled 18 charts

Breast Neoplasms

NCT02681523 2024-09-19

ALERT

8 enrolled 20 charts

Breast Neoplasms

NCT06539559 2024-08-06

Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer

60 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT06387628 2024-08-02

LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer

74 enrolled

Triple Negative Breast Neoplasms

NCT04464174 2024-07-26

PATHFINDER

54 enrolled

Triple Negative Breast Neoplasms

NCT02035813 2024-06-04

DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).

116 enrolled

Breast Neoplasms, Neoplastic Cells, Circulating

NCT02640508 2024-05-09

Eribulin and Lenvatinib in Advanced Solid Tumors

29 enrolled 13 charts

Tumor-Agnostic

Neoplasms

NCT06308939 2024-03-13

Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial

81 enrolled

Breast Neoplasms

NCT03051659 2024-03-06

A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer

90 enrolled 13 charts

Breast Neoplasms

NCT06202313 2024-01-11

Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer

128 enrolled

Triple Negative Breast Neoplasms

NCT05833919 2023-04-27

Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients

122 enrolled

Breast Neoplasms

NCT04303741 2023-04-12

A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC

46 enrolled

Breast Neoplasms

NCT05206656 2022-11-23

Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer

80 enrolled

Breast Neoplasms

NCT03810976 2022-06-16

A Study of Eribulin With Gemcitabine in Patients With Advanced Liposarcoma or Leiomyosarcoma

37 enrolled

NCT05402722 2022-06-02

Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer

30 enrolled

Triple Negative Breast Neoplasms

NCT02000596 2022-05-27

1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.

2 enrolled 7 charts

Breast Neoplasms

NCT04745975 2022-04-20

Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer

100 enrolled

Triple Negative Breast Neoplasms

NCT05263882 2022-03-03

Gemcitabine Combined With Eribulin Regimen in the Treatment of Second-line Above Recurrent HER2-negative Breast Cancer

58 enrolled

HER2-negative Breast Cancer

NCT02404506 2021-09-29

Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer

78 enrolled

Adenocarcinoma, Breast Neoplasms

NCT01593020 2021-09-22

Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2

54 enrolled 10 charts

Breast Neoplasms

NCT03795012 2021-08-31

Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients

22 enrolled

Breast Neoplasms, Neoplasm Metastasis, Recurrence

NCT04913571 2021-06-04

TEMPLATE

265 enrolled

Triple Negative Breast Neoplasms

NCT04624711 2021-05-21

Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer

40 enrolled

HER2-negative Breast Cancer

NCT04681911 2020-12-23

Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer

71 enrolled

Breast Neoplasms

NCT04517292 2020-08-18

GEP

160 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04502680 2020-08-11

EMBRAVE-001

100 enrolled

Triple Negative Breast Neoplasms

NCT02581839 2020-07-30

Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate